NASDAQ:CANC Tema Oncology ETF (CANC) Price, Holdings, & News $37.09 -0.88 (-2.32%) As of 05/15/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Oncology ETF (NASDAQ:CANC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tema Oncology ETF alerts:Sign Up Key Stats Today's Range$36.85▼$37.5050-Day Range$34.84▼$39.8252-Week Range$22.78▼$39.95Volume13,496 shsAverage Volume32,288 shsMarket Capitalization$173.95 millionAssets Under Management$175.43 millionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema. Read More Tema Oncology ETF ExpensesTypeCANCTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.55%0.51%0.55%Total Expense0.99%0.73%0.76%0.73%0.73%Fee Waiver-0.24%-0.74%-0.64%-0.50%-0.61%Net Expense0.75%0.60%0.63%0.62%0.60% Receive CANC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Oncology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANC ETF News HeadlinesTema ETFs Surpasses $2 Billion in AUM in Under Three YearsApril 16, 2026 | marketwatch.comCANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting StocksApril 10, 2026 | seekingalpha.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 17 at 1:00 AM | Banyan Hill Publishing (Ad)Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year.December 4, 2025 | msn.comTema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 PerformanceDecember 2, 2025 | businesswire.comSee More Headlines CANC ETF - Frequently Asked Questions How have CANC shares performed this year? Tema Oncology ETF's stock was trading at $34.72 at the beginning of 2026. Since then, CANC shares have increased by 6.8% and is now trading at $37.09. Who are Tema Oncology ETF's major shareholders? Top institutional shareholders of Tema Oncology ETF include Roxbury Financial LLC (0.02%). How do I buy shares of Tema Oncology ETF? Shares of CANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Oncology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Oncology ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NiCE (NICE) and Intellia Therapeutics (NTLA). Fund Details IssuerTema Global Fund NameTema Oncology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CANC Inception Date8/15/2023 Fund ManagerDavid Song WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings114 Fund Statistics Assets Under Management$175.43 million Average Daily Volume$0.00 Discount/Premium0.08% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema ETFs LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest8,600 shs Miscellaneous Outstanding Shares4,690,000Beta0.74 Creation Unit10,000 Creation Fee$500.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report Top 10 CANC HoldingsRevolution Medicines (NASDAQ:RVMD)Holding Weight: 7.31%Eli Lilly and Company (NYSE:LLY)Holding Weight: 4.25%Immunome (NASDAQ:IMNM)Holding Weight: 4.21%Cogent Biosciences (NASDAQ:COGT)Holding Weight: 4.08%Roche (OTCMKTS:RHHBY)Holding Weight: 4.07%Novartis AGHolding Weight: 4.00%Celcuity (NASDAQ:CELC)Holding Weight: 3.93%AstraZeneca PLCHolding Weight: 3.50%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 3.43%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 3.34%Full Holdings DetailsCANC Sector ExposureCANC Industry Exposure This page (NASDAQ:CANC) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the bigg...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
